dr. pal on potential tivozanib-based combinations in rcc
Published 4 years ago • 162 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
0:50
dr. pal on the benefit of tivozanib in later-line settings for refractory rcc
-
1:01
dr. pal on the potential use of parp inhibitors in rcc
-
0:52
dr. pal on the rationale for the tivo-3 trial with tivozanib in advanced rcc
-
1:00
dr. vaishampayan on the potential of tivozanib in advanced rcc
-
1:41
tivozanib tolerability shows potential advantage for patients with advanced rcc
-
7:03
a doctor reviews: plenity vs. other weight loss options
-
1:00:51
single cell analysis from a clinical perspective | ralph weissleder | scp2018
-
29:37
carnivorycon 2019: dr. zsófia clemens — “intestinal permeability in autoimmune diseases and cancer…
-
1:33
dr. pal on the checkmate-214 and cabosun studies in rcc
-
0:51
dr. pal on the safety profile of cabozantinib/atezolizumab in advanced rcc
-
0:41
dr. pal on molecular signatures in renal cell carcinoma
-
1:06
dr. pal on crispr-based technology in rcc
-
0:48
dr. pal on preoperative immunotherapy in patients with rcc
-
1:24
dr. motzer on the tivo-1 trial with tivozanib in advanced rcc
-
1:37
dr. shuch on caveats of avelumab/axitinib combination in rcc
-
0:48
dr. pal discusses the role of pd-l1 in metastatic rcc
-
1:32
dr. pal compares checkmate-214 and cabosun trials in rcc
-
0:59
dr. alva on tki monotherapy and combinations for rcc
-
1:31
dr. pal on biomarker development in renal cell carcinoma
-
3:01
potential immunotherapy combinations in rcc
-
1:01
dr. pal on sequencing challenges for the treatment of patients with rcc
-
2:00
dr. pal on adjuvant therapy of renal cell carcinoma